Wolfgang Eiermann

Wolfgang Eiermann

UNVERIFIED PROFILE

Are you Wolfgang Eiermann?   Register this Author

Register author
Wolfgang Eiermann

Wolfgang Eiermann

Publications by authors named "Wolfgang Eiermann"

Are you Wolfgang Eiermann?   Register this Author

62Publications

2259Reads

47Profile Views

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

N Engl J Med 2018 08 15;379(8):753-763. Epub 2018 Aug 15.

From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) - both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) - all in California; the Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München (J.E.), and Interdisziplinäres Onkologisches Zentrum München (W.E.) - both in Munich, Germany; Institut Paoli-Calmettes, Marseille (A.G.), and Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse (H.R.) - both in France; Seoul National University Hospital (K.-H.L.) and Samsung Medical Center (Y.-H.I.) - both in Seoul, South Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel (R.Y.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (L.A.M.); and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Oncología, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802905DOI Listing
August 2018

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

J Clin Oncol 2017 Jan 7;35(2):141-148. Epub 2016 Nov 7.

Edith A. Perez, Mayo Clinic, Jacksonville, FL; Howard Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Jennifer A. Petersen, Genentech, South San Francisco, CA; Carlos Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre, Brazil; Wolfgang Eiermann, Interdisciplinary Oncology Center, Munich, Germany; Masakazu Toi, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Young-Hyuck Im, Samsung Medical Centre, Seoul, Korea; Pierfranco Conte, University of Padova and Istituto Oncologico Veneto, Padova, Italy; Miguel Martin, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland; Xavier Pivot, University Hospital Jean Minjoz, Besançon, France; Sven Stanzel, Alexander Strasak, Monika Patre, F. Hoffmann-La Roche, Basel, Switzerland; and Paul Ellis, Guys Hospital and Sarah Cannon Research Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.4887
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.4887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677PMC
January 2017

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

J Clin Oncol 2016 10;34(29):3518-3528

Michael F. Press, Denice D. Tsao-Wei, Yanling Ma, Ivonne Villalobos, and Anaamika Campeau, University of Southern California Norris Comprehensive Cancer Center; Dennis J. Slamon, Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA; Nicholas Robert, Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Vicente Valero, The University of Texas MD Anderson Cancer Center, Houston, TX; Guido Sauter and Martina Mirlacher, University of Hamburg, Hamburg; Wolfgang Eiermann, Frauenklinik vom Roten Kreuz, Munich, Germany; Marc Buyse, Hélène Fourmanoir, and Emmanuel Quinaux, International Drug Development Institute, Louvain-la-Neuve, Belgium; Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland; John Crown, Irish Cooperative Onoclogy Research Group, St Vincent's University Hospital, Dublin, Ireland; Miguel Martin, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain; John R. Mackey, University of Alberta; Mary-Ann Lindsay, Cancer International Research Group/Translational Research in Oncology, Edmonton, Alberta, Canada; and Valerie Bee, Cancer International Research Group/Translational Research in Oncology, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.6693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074347PMC
October 2016

In Regard to Hepel and Wazer.

Int J Radiat Oncol Biol Phys 2015 Aug 14;92(5):953-954. Epub 2015 Jul 14.

Clinical Trials Group, Division of Surgery and Interventional Science, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.05.038DOI Listing
August 2015

PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.

PLoS One 2014 7;9(1):e84472. Epub 2014 Jan 7.

Department of Gynecology and Obstetrics, Red Cross Hospital, Munich, Germany ; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0084472PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883666PMC
September 2014

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Clin Cancer Res 2014 Jan;20(2):511-21

Authors' Affiliations: Translational Genomics Group, Vall d'Hebron Institute of Oncology; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona; Hospital Clinico Universitario, Valencia, Spain; Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy; Roche, Pharma Research and Early Development, Penzberg; Frauenklinik vom Roten Kreuz, Munich, Germany; University of North Carolina, Chapel Hill, North Carolina; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; NN Blokhin Russian Cancer Centre; Central Clinical Hospital named after N A Semashko, Moscow, Russia; and Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0239DOI Listing
January 2014

Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades.

Arch Gynecol Obstet 2013 Dec 5;288(6):1203-12. Epub 2013 Nov 5.

Department of Obstetrics and Gynaecology, J. W. Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-013-3069-4DOI Listing
December 2013

Response-guided neoadjuvant chemotherapy for breast cancer.

J Clin Oncol 2013 Oct 3;31(29):3623-30. Epub 2013 Sep 3.

Gunter von Minckwitz, Keyur Mehta, and Sibylle Loibl, Headquarters, German Breast Group, Neu-Isenburg; Jens Uwe Blohmer, St Gertrauden Krankenhaus, Berlin); Serban Dan Costa, Universitäts-Frauenklinik, Magdeburg; Carsten Denkert, Institute for Pathology, Charite, Berlin; Holger Eidtmann, Universitäts-Frauenklink, Kiel; Wolfgang Eiermann and Claus Hanusch, Klinikum zum Roten Kreuz, Munich; Bernd Gerber, Universitäts-Frauenklinik, Rostock; Jörn Hilfrich, Henrietten-Stiftung, Hanover; Jens Huober, Universitäts-Frauenklinik Tübingen, Frauenklinik; Christian Jakisch and Sibylle Loibl, Städtische Kliniken, Offenbach; Gunter von Minckwitz, Universitäts-Frauenklinik, Frankfurt; Sherko Kümmel, Klinikum Essen Mitte, Essen; Stefan Paepke, Universitäts-Frauenklinik rechts der Isar, Munich; Andreas Schneeweiss, National Center for Tumor Diseases, University of Heidelberg; Michael Untch, Helios-Klinikum, Berlin-Buch; Dirk Michael Zahm, Brustzentrum Stiftung Rehabilitation Heidelberg (SRH) Waldkliniken, Gera, Germany; Jens Huober, Kantonsspital, St Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.0940DOI Listing
October 2013

PTK7 expression in triple-negative breast cancer.

Anticancer Res 2013 Sep;33(9):3759-63

Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Henricistrasse 92, 45136 Essen, Germany.

View Article

Download full-text PDF

Source
September 2013

BRCA2 mutations and triple-negative breast cancer.

PLoS One 2012 30;7(5):e38361. Epub 2012 May 30.

Institute of Medical Genetics, University Hospital, Rostock, Germany.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038361PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364210PMC
October 2012

Bisphosphonates in the adjuvant treatment of early breast cancer: conclusion.

Crit Rev Oncol Hematol 2010 Apr;74 Suppl 1:S16-7

Frauenklinik vom Roten Kreuz, 80637 München, Germany.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428107000
Publisher Site
http://dx.doi.org/10.1016/S1040-8428(10)70006-8DOI Listing
April 2010

Technical improvement of pO(2) measurements in breast cancer: investigation of the feasibility in patients and in vitro validation of the method.

Strahlenther Onkol 2007 May;183(5):265-70

Department of Radiotherapy and Radiation Oncology, Klinikum rechts der Isar, Technische Universität, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-007-1573-9DOI Listing
May 2007

Increased prevalence of colorectal adenomas in women with breast cancer.

Digestion 2005 16;72(2-3):150-5. Epub 2005 Sep 16.

Department of Medicine II, University of Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000088370DOI Listing
January 2006

Reducing the global breast cancer burden: the importance of patterns of care research.

Clin Breast Cancer 2005 Dec;6(5):412-20

Loyola University Chicago Strich School of Medicine, Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2005.n.045DOI Listing
December 2005

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.

Breast Cancer Res Treat 2005 Jan;89(2):165-72

German Breast Group/Universitäts-Frauenklinik Frankfurt and Klinikum der Goethe-Universitaet, Zentrum für Frauenheilkunde and Geburtshilfe, Neu-Isenburg/Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-004-1720-2DOI Listing
January 2005

[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].

MMW Fortschr Med 2003 Dec;145(50)

View Article

Download full-text PDF

Source
December 2003

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.

Cancer 2002 Nov;95(9):2006-16

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.10908DOI Listing
November 2002